Business Standard – Bangalore-based Biocon entered into an agreement with Laboratorios PiSA of Mexico for the co-development and commercialization of generic recombinant human insulin (rh-insulin) for the US market. This collaboration is a part of Biocon’s strategy to address the large demand for generic rh-insulin in the US, which accounts for over 40 percent of the global sales of $5 billion.

http://www.business-standard.com/content/b2b-pharma/biocon-ties-up-with-mexico-s-pisa-to-tap-insulin-market-in-us-116031800308_1.html